Samsung Biologics and Biogen Idec have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars. The JV is part of the biosimilars agreement the companies announced in December. Christopher Hansung Ko has been named the chief executive officer of Samsung Bioepis. He previously served as senior vice president of Samsung Strategic Business Development. The JV’s board of directors will consist of five directors and one auditor. The strategic...